Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033071 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,071
- Enrollment target
NCT01033071 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,071 participants.
The verdict
NCT01033071, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,071 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
Interventions
- DRUG Azilsartan medoxomil and chlorthalidone
- DRUG Olmesartan medoxomil and hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,071 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01033071
The ClinicalTrials.gov registry entry for NCT01033071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,071 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azilsartan medoxomil and chlorthalidone is the first listed.
NCT01033071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01033071 about?
NCT01033071 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.". The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
What is the current status of trial NCT01033071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,071 participants. The study started on 2010-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01033071?
The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG), Olmesartan medoxomil and hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01033071?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.